Overview

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.
Phase:
Phase 1
Details
Lead Sponsor:
Azevan Pharmaceuticals
National Institute of Mental Health (NIMH)
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Arginine Vasopressin
SRX246
Vasopressins